NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at NewLink Genetics Corporation (“NewLink” or the “Company”) (NASDAQGM:NLNK).
The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that NewLink’s immunotherapy drug, indoximod, was not showing a meaningful benefit in its Phase 2 trial for patients with advanced melanoma.
Since the results of the Phase 2 trial were announced on April 4, 2017, the stock has dropped more than 10% on unusually heavy volume.
Request more information now by clicking here: www.faruqilaw.com/NLNK. There is no cost or obligation to you.
If you invested in NewLink stock or options between October 25, 2016 and April 3, 2017 and would like to discuss your legal rights, visit www.faruqilaw.com/NLNK. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding NewLink’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.